Loretta J. Nastoupil, MD

One of the most promising innovations in the multiple myeloma space has been the development of bispecific antibodies.

During a Targeted Oncology Case Based Peer Perspectives Roundtable event, Loretta J. Nastoupil, MD, discussed the case of a 74-year-old patients with diffuse large B-cell lymphoma.

Loretta J. Nastoupil, MD, discusses the use of off-the-shelf chimeric antigen receptor T-cell products for the treatment of patients with diffuse large B-cell lymphoma and other cancers.